Gemzar 200 Mg Injection is a nucleoside analog used as chemotherapy. It is marketed as Gemzar by Eli Lilly and Company. This medication is indicated for the treatment in various carcinomas: non-small cell lung cancer, pancreatic cancer, bladder cancer and breast cancer.
As with fluorouracil and other analogues of pyrimidines, the drug replaces one of the building blocks of nucleic acids, in this case cytidine, during DNA replication
The process arrests tumour growth, as new nucleosides cannot be attached to the "faulty" nucleoside, resulting in apoptosis (cellular "suicide")
It is being investigated for use in esophageal cancer, and is used experimentally in lymphomas and various other tumour types